Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002109299-26-000004
Filing Date
2026-02-17
Accepted
2026-02-17 16:55:06
Documents
1
Period of Report
2026-02-13

Document Format Files

Seq Description Document Type Size
1 form4-02172026_040201.html 4  
1 form4-02172026_040201.xml 4 6194
  Complete submission text file 0002109299-26-000004.txt   7600
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Issuer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 205 S FAIRVILLE ROAD CHADDS FORD PA 19317
Business Address
Bhalla Narinder Pal (Reporting) CIK: 0002109299 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41855 | Film No.: 26643086